Interleukin Genetics said that Kip Martha, its chief medical and regulatory officer, has left the company. Ken Kornman, Interleukin Genetics’ chief scientific officer, will oversee Martha’s responsibilities until the company hires a replacement.
The company has also hired three research directors: Terri Clark, formerly with Transkaryotic Therapies, will be director of clinical affairs; Leon Wilkins, formerly with Organogenesis, will be director of functional genetics; and John Rogus, formerly with the Joslin Diabetes Center, will be director of statistical genetics.
Diadexus has hired Krishna Sudhir as vice president of medical affairs. He joins Diadexus from Millennium Pharmaceuticals, where he was director of clinical research. Previously, he was director of cardiovascular research for Pharmacyclics, the company said last week.
In his new position, Sudhir will act as a liaison between the scientific and business aspects of marketing the PLAC test, a diagnostic that measures levels of Lp-PLA2, a risk factor for heart disease. The US Food and Drug Administration cleared the test for marketing in July 2003.
Sudhir has been a consulting associate professor of medicine in the cardiology division at Stanford University since 2001. He was an associate professor of medicine at Monash University, in Melbourne; consultant cardiologist at the Alfred Hospital; and co-director of the hormones and vasculature research laboratory at the Baker Heart Research Institute in Melbourne, Australia, from 1998-2001.
Sudhir received his MD from the University of Madras, India, in 1984 and his PhD in vascular physiology from Monash University in 1990.
Diadexus has also hired David Davidovic as vice president of marketing and sales. His role at Diadexus will be to commercialize the PLAC test. Davidovic joins Diadexus from Merck, where he most recently served as executive director of marketing.
Davidovic received a BS in physiology and an MBA in marketing/information systems from McGill University in Montreal, Canada.
Aclara BioSciences has appointed John Weinstein to its scientific advisory board, bringing to five the number of individuals on the board, the company said last week. Weinstein’s research focus is the molecular pharmacology of cancer cells using techniques such as gene expression profiling and bioinformatics, and the identification and characterization of new agents for the treatment of cancer.
Digene has appointed Kenneth Weisshaar to sit on its board of directors. His term ends in 2006, and increases to seven the number of directors on the company’s board.
Weisshaar was COO of Sensatex/Life Link from 2000 to 2003. He has also been, at one time or another, CFO, president of worldwide consumer health care, and sector president of the bioscience cell division at Becton, Dickinson.
GeneGo has appointed Sequenom CSO Charles Cantor to its scientific advisory board. Cantor is also a director of Sequenom and of the Center for Advanced Biotechnology at Boston University. In 2002, he founded SelectX Pharmaceuticals, which is based in Worcester, Mass.